Aardvark Therapeutics, Inc. Common Stock
AARD - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$30.42M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $30.42 Million |
|---|---|
| Enterprise Value | $-42,752,064.00 |
| Earnings per Share | $-2.64 |
| Beta | 3.81 |
| Outstanding Shares | 21,846,251 |
Return
| Return on Equity | -93.44% |
|---|---|
| Return on Assets | -85.80% |
| Return on Invested Capital | -93.09% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | -311.06 |
| Price to Sales | - |
| Price to Book Ratio | 0.5 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.61 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.87
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.72
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 5.60, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.
| Put/Call Ratio | 5.5986▲ 559.86% |
|---|---|
| Total Calls | 14,700▲ Infinity% |
| Total Puts | 82,300▲ 12.89% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 43.18%▼ 3.58% |
|---|---|
| Total Invested | $54.35M▲ 41.35% |
| Investors Holding | 75▼ 6.00% |
About Aardvark Therapeutics, Inc. Common Stock
28 employees
CEO: Tien-Li Lee
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate hom...